| 000 | 01872 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250518001358.0 | ||
| 264 | 0 | _c20190109 | |
| 008 | 201901s 0 0 eng d | ||
| 022 | _a1179-1918 | ||
| 024 | 7 |
_a10.1007/s40261-018-0705-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNazha, Sara | |
| 245 | 0 | 0 |
_aCost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence. _h[electronic resource] |
| 260 |
_bClinical drug investigation _cDec 2018 |
||
| 300 |
_a1155-1165 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Pragmatic Clinical Trial | ||
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xeconomics |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xeconomics |
| 650 | 0 | 4 |
_aCanada _xepidemiology |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xdrug therapy |
| 650 | 0 | 4 |
_aCost-Benefit Analysis _xtrends |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHealth Care Costs _xtrends |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIndazoles |
| 650 | 0 | 4 |
_aKidney Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPyrimidines _xeconomics |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 |
_aSulfonamides _xeconomics |
| 650 | 0 | 4 |
_aSunitinib _xeconomics |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aTanguay, Simon | |
| 700 | 1 | _aKapoor, Anil | |
| 700 | 1 | _aJewett, Michael | |
| 700 | 1 | _aKollmannsberger, Christian | |
| 700 | 1 | _aWood, Lori | |
| 700 | 1 | _aBjarnason, G A Georg | |
| 700 | 1 | _aHeng, Daniel | |
| 700 | 1 | _aSoulières, Denis | |
| 700 | 1 | _aReaume, Martin Neil | |
| 700 | 1 | _aBasappa, Naveen | |
| 700 | 1 | _aLévesque, Eric | |
| 700 | 1 | _aDragomir, Alice | |
| 773 | 0 |
_tClinical drug investigation _gvol. 38 _gno. 12 _gp. 1155-1165 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s40261-018-0705-6 _zAvailable from publisher's website |
| 999 |
_c28886226 _d28886226 |
||